One challenge in the atherectomy debate is treating “atherectomy” like a single device category.
As Dr. John Rundback explains, the AMBITION BTK trial (initiated by Angiodynamics) breaks that limitation by evaluating the Auryon Atherectomy System against POBA in both real-world BTK disease and chronic limb-threatening ischemia.
The result could be the clearest data set yet for operators deciding when and how to use these tools 👀
Go to Life Of Flow’s channel now for the full conversation with Dr. John Rundback.
